On May 15, 2014, Idera Pharmaceuticals Inc (NASDAQ:IDRA), Product Pipeline Review – 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Idera Pharmaceuticals, Inc.’s pharmaceutical research and development focus. Idera Pharmaceuticals Inc (NASDAQ:IDRA), weekly performance is -5.54%. On last trading day company shares ended up $2.56. Analysts mean target price for the company is $7.00. Idera Pharmaceuticals Inc (NASDAQ:IDRA), distance from 50-day simple moving average (SMA50) is -30.79%.
Acceleron Pharma Inc (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, reported that Acceleron, Celgene and investigators in the sotatercept and ACE-536 phase 2 clinical trials will give three oral presentations of interim data from ongoing studies in beta-thalassemia and myelodysplastic syndromes as well as a poster presentation of nonclinical data in sickle cell disease at the 19th Annual Congress of the European Hematology Association (EHA) in Milan, Italy from June 12-15, 2014. Acceleron Pharma Inc (NASDAQ:XLRN), advanced 6.12% in last trading session and ended the day on $31.23. XLRN, return on assets is -37.40%. Acceleron Pharma Inc (NASDAQ:XLRN),quarterly performance is -34.24%.
On May 14, 2014, Puma Biotechnology Inc (NYSE:PBYI), a development stage biopharmaceutical company, has expanded the first cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). Puma Biotechnology Inc (NYSE:PBYI), shares moved up 11.77% in last trading session and was closed at $73.11, while trading in range of $65.33 – 73.31. Puma Biotechnology Inc (NYSE:PBYI), year to date (YTD) performance is -29.38%.
On May 12, 2014, DARA Biosciences Inc (NASDAQ:DARA), announced its first quarter 2014 results. For the first quarter ended March 31, 2014, DARA reported a net loss attributable to controlling interest of ($2,658,081), or ($0.37) per share as compared to a net loss attributable to controlling interest of ($2,522,588), or ($0.55) per share for the first quarter ended March 31, 2013. As of March 31, 2014, cash and cash equivalents totaled $6,828,100. DARA Biosciences Inc (NASDAQ:DARA), ended the last trading day at $1.09. Company weekly volatility is calculated as 12.59% and price to cash ratio as 2.69. DARA Biosciences Inc (NASDAQ:DARA), showed a negative weekly performance of 3.54%.
On May 12, 2014, Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, announced topline results from its Phase 1 onset-of-action study of patiromer, the final clinical trial planned to support a New Drug Application (NDA), which the company expects to submit to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014. Relypsa Inc (NASDAQ:RLYP), weekly performance is 9.34%. On last trading day company shares ended up $25.41. Analysts mean target price for the company is $52.67. Relypsa Inc (NASDAQ:RLYP), distance from 50-day simple moving average (SMA50) is -9.11%.